- Report
- September 2026
- 180 Pages
Global
From €3194EUR$3,545USD£2,741GBP
€3549EUR$3,939USD£3,045GBP
- Report
- September 2026
- 191 Pages
Global
From €5271EUR$5,850USD£4,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4046EUR$4,490USD£3,471GBP
- Report
- February 2026
- 250 Pages
Global
From €4046EUR$4,490USD£3,471GBP
- Report
- July 2026
- 115 Pages
Global
From €4280EUR$4,750USD£3,672GBP
- Report
- August 2026
- 160 Pages
Global
From €2992EUR$3,320USD£2,567GBP
€3739EUR$4,150USD£3,208GBP
- Report
- October 2025
- 160 Pages
Global
From €2847EUR$3,160USD£2,443GBP
€3559EUR$3,950USD£3,054GBP
- Report
- September 2026
- 291 Pages
Global
From €5271EUR$5,850USD£4,522GBP
- Report
- April 2026
- 200 Pages
Global
From €2694EUR$2,990USD£2,311GBP
- Report
- June 2026
- 150 Pages
Global
From €5361EUR$5,950USD£4,600GBP
- Report
- January 2026
- 193 Pages
Global
From €3194EUR$3,545USD£2,741GBP
€3549EUR$3,939USD£3,045GBP
- Report
- October 2025
Global
From €4415EUR$4,900USD£3,788GBP
- Report
- September 2026
- 186 Pages
Global
From €3194EUR$3,545USD£2,740GBP
€3549EUR$3,939USD£3,045GBP
- Report
- September 2026
- 195 Pages
Global
From €3194EUR$3,545USD£2,740GBP
€3549EUR$3,939USD£3,045GBP
- Report
- September 2026
- 199 Pages
Global
From €3194EUR$3,545USD£2,740GBP
€3549EUR$3,939USD£3,045GBP
- Report
- January 2026
- 194 Pages
Global
From €3194EUR$3,545USD£2,741GBP
€3549EUR$3,939USD£3,045GBP
- Report
- January 2026
- 182 Pages
Global
From €3194EUR$3,545USD£2,741GBP
€3549EUR$3,939USD£3,045GBP
- Report
- January 2026
- 191 Pages
Global
From €3194EUR$3,545USD£2,741GBP
€3549EUR$3,939USD£3,045GBP
- Report
- January 2026
- 199 Pages
Global
From €3194EUR$3,545USD£2,741GBP
€3549EUR$3,939USD£3,045GBP
- Report
- January 2026
- 198 Pages
Global
From €3194EUR$3,545USD£2,741GBP
€3549EUR$3,939USD£3,045GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more